Session » T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1727

BATF Represses BIM Expression to Sustain the T Cell Anergy Program

1:00PM-3:00PM: Abstract Number: 1747

Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1738

Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases

1:00PM-3:00PM: Abstract Number: 1740

Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity

1:00PM-3:00PM: Abstract Number: 1735

Clonally Expanded Cytotoxic CD8+ T Cells Recognize Citrullinated Antigens in ACPA+ Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1748

Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion

1:00PM-3:00PM: Abstract Number: 1745

Effects of Excess IL-18 in Mixed Inflammatory Environments

1:00PM-3:00PM: Abstract Number: 1733

Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium

1:00PM-3:00PM: Abstract Number: 1743

Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment

1:00PM-3:00PM: Abstract Number: 1734

Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics

1:00PM-3:00PM: Abstract Number: 1736

IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells

1:00PM-3:00PM: Abstract Number: 1744

Immune Responses to mRNA Vaccines Against SARS-CoV-2 in Patients with Immune-mediated Inflammatory Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1737

In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature

1:00PM-3:00PM: Abstract Number: 1746

Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response

1:00PM-3:00PM: Abstract Number: 1728

Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1749

Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1741

Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model

1:00PM-3:00PM: Abstract Number: 1732

Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1742

Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA

1:00PM-3:00PM: Abstract Number: 1739

Single-Cell Characterization of the TCR Repertoire Across Tissue and Blood in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1729

SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1731

Systemic Sclerosis-Associated Class II HLA Alleles Restrict the Diversity of the CDR3 and the T Cell Receptor Repertoire in African American Patients

1:00PM-3:00PM: Abstract Number: 1730

T Cell-Macrophage Interactions Play a Critical Role in a Mouse Model of Histidyl-tRNA Synthetase-Induced Myositis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].